AI-powered synthesis planning

The synthesis
planning OS
for chemistry.

Built for chemists. Grounded in a decade of AI research.

The problem

We've learned to design molecules in hours. Making them still takes weeks.

Finding a viable route still relies on the intuition of experienced chemists and hours of manual literature searching. That knowledge is hard to scale and walks out the door when people leave.

Proposed routes often ignore what's actually in stock or quickly obtainable. Chemists lose days waiting on building blocks or reworking plans that were never practical.

When a reaction doesn't work, teams go back to square one. Each iteration adds weeks, and across a portfolio those delays compound into months lost before a compound is ever tested.

Our solution

State-of-the art AI platform built on 10+ years of AI & cheminformatics research.

MoleculR integrates three purpose-built layers to give chemists synthesis plans that are feasible, contextualised, and sourcing-aware at scale.

alexandRia
Database · v0.1
Currently containing 72K routes and 414K reactions.

A curated synthesis database built through our own extraction pipeline: structured routes with context from patents and high-quality literature.

aRistotle
Algorithm · v0.1
In development

A proprietary engine delivering synthesis feasibility, reaction pathways, and full context. Extensible with your internal data for on-premise deployment.

aRgo
Platform · v0.1
In development

The chemist-facing interface: test, explore, and refine reaction plans with AI tools, integrated with up-to-date compound catalogues from leading suppliers.

Where we are

From research to platform — on schedule.

2025
Founding of MoleculR
Team assembled. Research foundation laid. Database pipeline initiated.
Now
Building alexandRia & aRistotle
Growing our curated synthesis database and refining the core algorithm.
Q4 2026
aRgo platform launch
First version of the synthesis planning platform goes live.
Q1 2027
Partner testing & refinement
aRgo testing and refining with early pharma and CDMO partners.
Get in touch

Interested in early access or a partnership?

We're working with a small group of pharma and biotech partners ahead of launch. If you'd like to be involved — or just learn more — reach out.

Or email us directly at hello@moleculr.ai